Peer Elshoff - Dokumente zum Namen - alle Infos bei Yasni.de

(1 - 15 von 16

)

Long‐term safety and efficacy of adjunctive brivaracetam in ...Wiley Online Library

onlinelibrary.wiley.com

von L Lagae · · Zitiert von: 1 — ... Peer Elshoff,. Jan-Peer Elshoff. UCB Pharma, Monheim am Rhein, Germany. Search for more papers by this author · Sofia Fleyshman,. Sofia ... von L Lagae · · Zitiert von: 1 — ... Peer Elshoff,. Jan-Peer Elshoff. UCB Pharma, Monheim am Rhein, Germany. Search for more papers by this author · Sofia Fleyshman,. Sofia ...

Efficacy and tolerability of brivaracetam monotherapy in ...ProQuest

search.proquest.com

von T Bast · · Zitiert von: 4 — Jan- Peer Elshoff, UCB Pharma, Alfred-. , Monheim,. Germany. . Funding information. UCB Pharma, Grant/Award ... von T Bast · · Zitiert von: 4 — Jan- Peer Elshoff, UCB Pharma, Alfred-. , Monheim,. Germany. . Funding information. UCB Pharma, Grant/Award ...

Pharmacokinetics and safety of brivaracetam in neonates ...Wiley Online Library

onlinelibrary.wiley.com

von R Pressler · Zitiert von: 1 — Jan-Peer Elshoff,. Jan-Peer Elshoff. UCB Pharma, Monheim am Rhein, Germany. Search for more papers by this author · John van den Anker,. John ... von R Pressler · Zitiert von: 1 — Jan-Peer Elshoff,. Jan-Peer Elshoff. UCB Pharma, Monheim am Rhein, Germany. Search for more papers by this author · John van den Anker,. John ...

Cognitive-and-Behavioral-Effects-of-Adjunctive-Brivaracetam ...aesnet.org

aesnet.org

— Jan-Peer Elshoff, PharmD, PhD – UCB Pharma; Sofia Fleyshman, BSc, MSc – UCB Pharma; Christine De la Loge, MSc – PCOM Analytics; Najla — Jan-Peer Elshoff, PharmD, PhD – UCB Pharma; Sofia Fleyshman, BSc, MSc – UCB Pharma; Christine De la Loge, MSc – PCOM Analytics; Najla ...

Long-term-Safety-and-Efficacy-of-Adjunctive-Brivaracetam-in ...aesnet.org

aesnet.org

— ... Peer Elshoff, PharmD, PhD – UCB Pharma; Sofia Fleyshman, BSc, MSc – UCB Pharma; Harriet Kang, MD – Neurology – Icahn School of Medicine at — ... Peer Elshoff, PharmD, PhD – UCB Pharma; Sofia Fleyshman, BSc, MSc – UCB Pharma; Harriet Kang, MD – Neurology – Icahn School of Medicine at ...

Paediatric posology and the EMA-endorsed graphical dose ...occams.com

www.occams.com

— 2Rik Schoemaker, Walter Krauwinkel, Jan-Peer Elshoff, Armel Stockis. Brivaracetam exposure-response predictions in pediatric patients from — 2Rik Schoemaker, Walter Krauwinkel, Jan-Peer Elshoff, Armel Stockis. Brivaracetam exposure-response predictions in pediatric patients from ...

pharmacokinetics and tolerability of single-dose staccato ...aesnet.org

aesnet.org

— ... Peer Elshoff, PhD – UCB Pharma, Monheim am Rhein, Germany; Robert Roebling, MD – UCB Pharma, Monheim am Rhein, Germany; Aliceson King, MD — ... Peer Elshoff, PhD – UCB Pharma, Monheim am Rhein, Germany; Robert Roebling, MD – UCB Pharma, Monheim am Rhein, Germany; Aliceson King, MD ...

Efficacy and tolerability of brivaracetam monotherapy in ...John Wiley

onlinelibrary.wiley.com

von T Bast · · Zitiert von: 1 — Anne-Liv Schulz, Florin Floricel, Diego Morita, Jody Cleveland, and Jan-Peer Elshoff are salaried employees of UCB Pharma and have received ...

Abstract DetailsAmerican Academy of Neurology (AAN)

www.aan.com

Authors/Disclosures. Jan-Peer Elshoff, PhD (Schwarz Biosciences GmbH), Dr. Elshoff has nothing to disclose. Barbara E. Graves, DO, No disclosure on file. Authors/Disclosures. Jan-Peer Elshoff, PhD (Schwarz Biosciences GmbH), Dr. Elshoff has nothing to disclose. Barbara E. Graves, DO, No disclosure on file.